CD38 and hypertensive disorder: In addition, no differences of NAD+ levels (Supplementary Fig. S21i) between WT mice and WT recipient mice (KO > WT or WT > WT) were observed, suggesting that the vascular CD38 instead of immunocyte CD38 contributed to NAD+ reduction related BP elevation and vascular damage in hypertension.